Wall St Engine(@wallstengine):$CAPR says Deramiocel’s BLA remains under active FDA review and it continues to see a path to approval despite the 3-9 AdCom vote. Capricor also ended Q2 with ~$238M in cash and says it has enough liquidity to fund operations for at least the next 12 months, reducing near-term financing concerns. The company highlighted that HOPE-3 met its primary upper-limb endpoint at p=0.029, while the AdCom was not asked to vote on that endpoint or overall benefit-risk. A regulatory update is expected on today’s 4:30 PM ET call.

2026.08.13 21:04

$CAPR says Deramiocel’s BLA remains under active FDA review and it continues to see a path to approval despite the 3-9 AdCom vote. Capricor also ended Q2 with ~$238M in cash and says it has enough liquidity to fund operations for at least the next 12 months, reducing near-term financing concerns. The company highlighted that HOPE-3 met its primary upper-limb endpoint at p=0.029, while the AdCom was not asked to vote on that endpoint or overall benefit-risk. A regulatory update is expected on today’s 4:30 PM ET call.